TP53 and cancer: In consideration of the fact that the paradigm of cancer treatment shifts from broadly acting genotoxic agents to biologically targeted therapies, the prospect of targeting MDM2 to reactivate p53 holds promise for the molecular therapy of neuroblastoma.